其中第三季度，公司营业收入为 55.4亿元 ，同比下降6.7%；归母净利润为 17.2亿元 ，同比下降3.8%；扣非归母净利润为1 6.5亿元，同比 下降4.1%。 【DT新材料】 获悉， 10月28日晚间，新和成(002001)公布2025年三季报， 公司营业收入为166.4亿元，同比上升5.5%；归母净利润为53.2亿元，同比 上升33.4% ；扣非归母净利润为53.3亿元，同比上升37.4%；经营现金流净额为56.42亿元，同比增长23.3%。 新和成是一家主要从事营养品、香精香料、高分子材料、原料药生产和销售的国家级高新技术企业。 从业务结构来看，新和成 营养品、香精香料、新材料三大主业 呈现差异化发展态势，多元布局有效平衡了单一市场波动带来的影响。 1. 营养品：传统基石盈利增强 作为公司核心支柱板块，营养品 2025 年上半年实现营收72亿元，同比增长7.78%，占总营收的 64.86%，仍是营收贡献的绝对主力。更值得关注的是，该 板块毛利率同比提升11.93个百分点至47.79%，盈利能力显著增强，主要受益于上半年维生素市场的高景气度。 2. 香精香料：稳健增长的利润压舱石 香精香料板块延续稳健 ...

（记者 王晓波） 每经AI快讯，开源证券10月30日发布研报称，给予新和成（002001.SZ，最新价：24.24元）"买入"评 级。评级理由主要包括：1）2025前三季度业绩同比高增、符合预期，稳步推进液蛋、尼龙新材料项目 等；2）蛋氨酸景气上行助力盈利能力修复，稳步推进新项目、新产品带来成长动力。风险提示：维生 素、蛋氨酸行业竞争加剧，项目投产不及预期，汇率波动等。 每日经济新闻 每经头条（nbdtoutiao）——"十五五"规划建议的18个新提法，释放了哪些重要信号？ 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 ...

证券研究报告 | 2025年10月30日 | 晨会纪要 | | --- | | 数据日期:2025-10-29 | 上证综指 | 深证成指沪深 | 300 指数 | 中小板综指 | 创业板综指 | 科创 50 | | --- | --- | --- | --- | --- | --- | --- | | 收盘指数（点） | 4016.33 | 13691.38 | 4747.83 | 14575.49 | 3987.65 | 1489.12 | | 涨跌幅度（%） | 0.70 | 1.94 | 1.19 | 1.20 | 1.77 | 1.18 | | 成交金额（亿元） | 9682.15 | 12878.14 | 6458.98 | 4348.39 | 6166.45 | 861.54 | $\frac{10}{100}\sum\limits_{\begin{subarray}{c}\text{\rm{B}}\\ \text{\rm{B}}\end{subarray}}\frac{10}{100}\sum\limits_{\begin{subarray}{c}\text{\rm{B}}\\ \text{\ ...

投资评级：买入（维持） | 日期 | 2025/10/28 | | --- | --- | | 当前股价(元) | 23.36 | | 一年最高最低(元) | 25.39/19.52 | | 总市值(亿元) | 717.95 | | 流通市值(亿元) | 709.41 | | 总股本(亿股) | 30.73 | | 流通股本(亿股) | 30.37 | | 近 3 个月换手率(%) | 54.73 | 股价走势图 数据来源：聚源 -20% -10% 0% 10% 20% 30% 2024-10 2025-02 2025-06 新和成 沪深300 相关研究报告 《业绩符合预期，蛋氨酸、香精香料 盈利稳中有增—公司信息更新报告》 -2025.8.28 《Q1 业绩高增，看好新项目、新产品 放量—公司信息更新报告》-2025.4.29 《营养品景气上行助力业绩高增，新 项目成长动力充足—公司信息更新报 告》-2025.4.16 基础化工/化学制品 新和成（002001.SZ） 2025 年 10 月 29 日 业绩符合预期，稳步推进液蛋、尼龙新材料项目 ——公司信息更新报告 | 金益腾（分析师） | 徐正凤（分析师 ...

Investment Rating - The report maintains an "Outperform" rating for the company [2] Core Views - The company reported slightly better-than-expected performance for the first three quarters of 2025, with total revenue of 16.642 billion yuan (yoy +5%) and net profit attributable to shareholders of 5.321 billion yuan (yoy +33%) [7] - The company is leveraging volume to compensate for price declines in vitamins, with a notable increase in liquid egg production contributing to profitability [7] - The vitamin market is showing signs of recovery after a downturn, with expectations of improved profitability due to reduced inventory levels and price stabilization [7] - The company is advancing its new materials projects and expanding into the pesticide market, enhancing its "Chemicals+" and "Biology+" platforms [7] Financial Summary - For 2025, the company is projected to achieve total revenue of 23.936 billion yuan, with a net profit of 6.510 billion yuan, reflecting a growth rate of 10.8% and 10.9% respectively [6] - The gross margin is expected to be 41.2% in 2025, with a return on equity (ROE) of 19.0% [6] - The company's earnings per share (EPS) is forecasted to be 2.12 yuan in 2025, with a price-to-earnings (PE) ratio of 11 [6]

Core Insights - The report highlights concerns regarding the independence of the Federal Reserve, particularly in light of political pressures, which may impact the macroeconomic narrative and the valuation of the US dollar [2] - The report provides a detailed analysis of various companies, focusing on their financial performance and strategic initiatives [3][4][5][6][7][8][10][11][12][17][19][20][22][24][25][26][27][28][30][31] Company Summaries - **Lihigh Food (300973 CH, Buy)**: The company reported revenue of 3.14 billion and net profit of 250 million for the first three quarters of 2025, showing year-on-year growth of 15.7% and 22.0% respectively. Despite pressure on gross margins due to rising palm oil prices, effective cost control has helped maintain profitability [3] - **Red Flag Chain (002697 CH, Accumulate)**: The company achieved revenue of 7.11 billion in the first three quarters of 2025, a year-on-year decrease of 8.5%. The net profit was 383 million, down 1.9% year-on-year. The company is focusing on internal management and cost reduction to improve profitability [4] - **Kanglong Chemical (300759 CH, Buy)**: The company reported revenue of 10.086 billion and adjusted net profit of 1.227 billion for the first three quarters of 2025, reflecting year-on-year growth of 14.4% and 10.8% respectively. The company has raised its revenue growth guidance for 2025 from 10-15% to 12-16% [5] - **Zhou Dasheng (002867 CH, Buy)**: The company reported revenue of 6.772 billion for the first three quarters of 2025, a decline of 37.3% year-on-year, while net profit increased by 3.1%. The growth in net profit is attributed to a higher proportion of high-margin products [6] - **Aimeike (300896 CH, Buy)**: The company reported revenue of 566 million in Q3 2025, down 21.3% year-on-year, with a net profit of 304 million, down 34.6%. The company is focusing on expanding its product pipeline and international market presence [7] - **Leixin Technology (688018 CH, Accumulate)**: The company achieved revenue of 1.912 billion in the first three quarters of 2025, a year-on-year increase of 30.97%. Despite a slight decline in Q3 revenue, the company is expanding its market presence in high-performance SoC [8] - **Zhongke Chuangda (300496 CH, Buy)**: The company reported revenue of 5.148 billion for the first three quarters of 2025, reflecting a year-on-year increase of 39.34%. The growth is driven by the AIOT sector [9] - **Yihua (301029 CH, Buy)**: The company reported revenue of 736 million in Q3 2025, up 17.52% year-on-year, with a net profit of 136 million, up 28.59%. The growth is attributed to the continued demand in lithium battery and automotive sectors [10] - **Huazhi Technology (688281 CH, Buy)**: The company reported revenue of 285 million in Q3 2025, a year-on-year increase of 12.85%. The company is focusing on its leading position in stealth materials [11] - **Chengdu Bank (601838 CH, Buy)**: The bank reported a net profit of 5.0% and revenue growth of 3.0% for the first nine months of 2025, indicating stable performance despite non-interest income fluctuations [12] - **Yun Tianhua (600096 CH, Buy)**: The company reported revenue of 12.6 billion in Q3 2025, a year-on-year decrease of 14%, but net profit increased by 24%. The company benefits from strong export demand for phosphate products [13] - **Funi Co., Ltd. (600483 CH, Buy)**: The company reported revenue of 3.666 billion in Q3 2025, down 4.04% year-on-year, but net profit increased by 11.53%. The company is focusing on its project reserves and renewable energy contributions [14] - **Hongcheng Environment (600461 CH, Buy)**: The company reported revenue of 1.738 billion in Q3 2025, up 2.41% year-on-year, with net profit of 324 million, reflecting stable operational performance [15] - **Op Lighting (603515 CH, Accumulate)**: The company reported revenue of 1.692 billion in Q3 2025, down 0.59% year-on-year, with net profit of 208 million, down 12.22%. The company is expected to recover as the housing market stabilizes [16] Industry Insights - The macroeconomic environment is influenced by political pressures on the Federal Reserve, which may affect market confidence and asset valuations [2] - The food and beverage sector is experiencing mixed performance, with some companies managing to maintain profitability through cost control and strategic initiatives [3][4][5][6] - The healthcare and pharmaceutical sectors are showing resilience, with companies reporting steady revenue growth and improved cash flow [7][8][9] - The technology sector, particularly in AI and IoT, is witnessing significant growth, driven by increased demand for advanced solutions [10][11][12] - The banking sector is showing stable performance, with banks managing to maintain profitability despite fluctuations in non-interest income [13][14] - The energy sector is focusing on renewable energy projects, with companies looking to expand their project reserves and improve operational efficiency [15][16]

Core Insights - The report highlights the acceleration of demand and continuous improvement in profitability for the companies analyzed, particularly in the semiconductor and copper industries, with significant year-on-year growth in revenue and net profit [12][13][14]. Company Summaries Unigroup Guowei (002049.SZ) - The company reported a revenue of 4.904 billion yuan for Q1-Q3 2025, representing a 15.1% year-on-year increase, and a net profit of 1.263 billion yuan, up 25.0% year-on-year [12]. - In Q3 2025 alone, revenue reached 1.857 billion yuan, a 33.6% increase year-on-year, with net profit soaring by 109.6% to 571 million yuan [12]. - The growth is attributed to the recovery in special business demand, stable development in traditional consumer markets, and accelerated expansion in eSIM and automotive safety chips [14]. Luoyang Copper (603993) - The company achieved a revenue of 145.49 billion yuan for Q1-Q3 2025, a decrease of 6.0% year-on-year, but net profit surged by 72.6% to 14.28 billion yuan, driven by rising copper prices and increased production and sales [13][14]. - Q3 2025 revenue was 50.71 billion yuan, down 2.4% year-on-year but up 4.0% quarter-on-quarter, with net profit increasing by 96.4% year-on-year to 5.61 billion yuan [14]. - The company plans to invest in the KFM Phase II project, expected to commence production in 2027, and has acquired Lumina Gold Company to diversify its mineral portfolio [14]. Other Companies - The report also covers various companies such as Nanjing Bank, which reported a revenue of 419 billion yuan for 9M25, up 8.8% year-on-year, and a net profit of 180 billion yuan, up 8.1% year-on-year, indicating a stable performance [20]. - New Australia Co. is highlighted for benefiting from the rising prices of Australian wool, with expectations of significant performance elasticity due to favorable supply and demand dynamics [19]. Industry Insights - The semiconductor industry is experiencing a new cycle of prosperity, driven by increased demand for special integrated circuits and advancements in high-end AI visual perception and automotive electronics [14]. - The copper industry is seeing a rebound in prices and production, with companies like Luoyang Copper capitalizing on this trend to enhance profitability and expand operations [14]. - The report emphasizes the importance of technological modernization and structural optimization in traditional industries as key components of future growth strategies [11].

证券研究报告 新和成 (002001 CH) 蛋氨酸助力公司业绩稳固 | 华泰研究 | | | 季报点评 | 投资评级(维持): | 增持 | | --- | --- | --- | --- | --- | --- | | 2025 年 | 10 月 | 29 日│中国内地 | 化学制品 | 目标价(人民币): | 25.68 | 新和成公布三季度业绩：Q3 实现营收 55.4 亿元（yoy-7%，qoq-2%），归 母净利 17.2 亿元（yoy-4%，qoq-0.4%）。2025 年 Q1-Q3 实现营收 166 亿元（yoy+5%），归母净利 53.2 亿元（yoy+33%），扣非净利 53.3 亿元 （yoy+37%）。公司 Q3 归母净利润超出我们预测（15.5 亿元），主要系 投资净收益等有所增加。考虑蛋氨酸等产品格局较好下高盈利有望维持，新 材料及香精香料业务稳步发展，维持"增持"评级。 蛋氨酸等价格同比上涨，25Q1-3 公司毛利率同比+6pct 至 46% 据百川盈孚，25 年前三季度维生素 A（50 万 IU/g）/维生素 E（50%）/蛋 氨酸（固体）市场均价达 81/99/22 元/千 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [4] Core Insights - The company's resilience in the nutrition sector is highlighted, with Q3 performance exceeding expectations. For the first three quarters of 2025, revenue reached 16.642 billion yuan, a year-on-year increase of 5.45%, while net profit attributable to shareholders was 5.321 billion yuan, up 33.37% year-on-year. However, Q3 revenue was 5.541 billion yuan, down 6.66% year-on-year and 2.11% quarter-on-quarter, with net profit at 1.717 billion yuan, down 3.80% year-on-year and 0.35% quarter-on-quarter [1][2] Summary by Sections Revenue and Profitability - In Q3 2025, the average prices for key products such as VA, VE, VC, and methionine were 63.3, 64.3, 19.2, and 22.3 yuan per kilogram, showing significant year-on-year declines of -67.4%, -48.7%, -27.5%, and an increase of +7.9% respectively. Despite the price drops, the company's gross margin was 44.86%, up 1.3 percentage points year-on-year, indicating strong profitability [2] Market Demand and Supply - The demand for methionine is expected to remain robust, with a projected global market growth of around 6% annually, translating to an increase of over 100,000 tons per year. The company plans to expand its solid methionine production capacity by 70,000 tons and has initiated trial production of an 180,000 tons/year liquid methionine project [3] Earnings Forecast and Valuation - The forecast for net profit attributable to shareholders for 2025-2027 is 6.61 billion, 7.04 billion, and 8.10 billion yuan respectively, with corresponding EPS of 2.15, 2.29, and 2.64 yuan. The current price corresponds to P/E ratios of 10.86, 10.20, and 8.86 for the respective years [4]

Core Viewpoint - The medical innovation sector is experiencing a structural recovery, with significant inflows into the Medical Innovation ETF and positive performance from key companies in the sector [1][2]. Group 1: Market Performance - On October 29, the Medical Innovation ETF (516820.SH) fell by 1.28%, with component stocks showing mixed results; Chuaning Biological (301301) led gains at 5.12%, while Ailis (688578) saw the largest decline at 5.13% [1]. - The Medical Innovation ETF has seen continuous net inflows over the past five days, with a peak single-day net inflow of 38.68 million yuan, totaling 66.42 million yuan and an average daily net inflow of 13.28 million yuan [1]. Group 2: Industry Trends - The pharmaceutical sector has undergone a prolonged valuation adjustment, but a significant structural recovery trend has emerged recently, supported by policies promoting commercial insurance development [1]. - The investment and financing landscape in the pharmaceutical sector is expected to recover, driven by a rebound in the secondary market, with continued positive sentiment in the CXO and upstream segments [1]. - Recent quarterly reports from several CXO companies, including WuXi AppTec, Tigermed, and others, indicate a positive outlook for the industry [1]. Group 3: Future Outlook - The CXO sector continues to show strong performance, with companies like WuXi AppTec and Boteng surpassing expectations in their quarterly results [2]. - The innovative drug sector is on a long-term upward trend, with opportunities arising from both domestic revenue growth and international expansion [2]. - The expectation of interest rate cuts in the U.S. is likely to enhance global liquidity and support the trend in technology stocks, providing an opportunity for investors to capitalize on the rebound in core pharmaceutical assets through the Medical Innovation ETF [2].